Overview

ADAPTING MEDICLINIC TO THE CHANGING GLOBAL HEALTHCARE ENVIRONMENT

is a priority with focus throughout the Group to invest across the continuum of care

750 000

INPATIENT ADMISSIONS

across the Group as the demand for quality healthcare services remains strong

REVENUE UP

2%

to £2 932m; up 4% in constant currency

ADJUSTED EBITDA DOWN

4%

to £493m; down 2% in constant currency reflecting the financial impact of regulatory changes on Hirslanden

LOSS OF

£151M*

impacted by non-cash Hirslanden and Spire impairment charges and other exceptional items

* Refer to loss attributable to equity holders.

£232M

SIGNIFICANT ONGOING INVESTMENT

across the Group supporting patient experience, clinical excellence, maintenance, upgrades and expansion

ADJUSTED EARNINGS PER SHARE DOWN

10%

to 26.9 pence

TOTAL DIVIDEND FOR THE YEAR

7.9 PENCE